PDF(Pubmed)
Abstract：
UNASSIGNED: This prospective multicenter phase II study aimed to evaluate the safety and efficacy of dynamic tumor tracking (DTT) stereotactic body radiotherapy (SBRT) with real-time monitoring of liver tumors using a gimbal-mounted system.
UNASSIGNED: Patients with < 4 primary or metastatic liver tumors with diameters ≤ 50 mm and expected to have a respiratory motion of ≥ 10 mm were eligible. The prescribed dose was 40 Gy in five fractions. The primary endpoint was local control (LC) at 2 years. The secondary endpoints were overall survival (OS), progression-free survival (PFS), treatment-related toxicity, and tracking accuracy.
UNASSIGNED: Between September 2015 and March 2019, 48 patients (48 lesions) with a median age of 74 years were enrolled from four institutions. Of these, 39 were diagnosed with hepatocellular carcinoma and nine with metastatic liver cancer. The median tumor diameter was 17.5 mm. DTT-SBRT was successfully performed in all patients; the median treatment time was 28 min/fraction. The median follow-up period was 36.5 months. The 2-year LC, OS, and PFS rates were 98.0 %, 88.8 %, and 55.1 %, respectively. Disease progression was observed in 33 (68.8 %) patients. One patient (0.2 %) had local recurrence, 31 (64.6 %) developed new hepatic lesions outside the irradiation field, and nine (18.8 %) had distant metastases (including overlap). Grade 3 late adverse events were observed in seven patients (14.5 %). No grade 4 or 5 treatment-related toxicity was observed. The median tracking accuracy was 2.9 mm.
UNASSIGNED: Employing DTT-SBRT to treat liver tumors results in excellent LC with acceptable adverse-event incidence.
UNASSIGNED: Patients with < 4 primary or metastatic liver tumors with diameters ≤ 50 mm and expected to have a respiratory motion of ≥ 10 mm were eligible. The prescribed dose was 40 Gy in five fractions. The primary endpoint was local control (LC) at 2 years. The secondary endpoints were overall survival (OS), progression-free survival (PFS), treatment-related toxicity, and tracking accuracy.
UNASSIGNED: Between September 2015 and March 2019, 48 patients (48 lesions) with a median age of 74 years were enrolled from four institutions. Of these, 39 were diagnosed with hepatocellular carcinoma and nine with metastatic liver cancer. The median tumor diameter was 17.5 mm. DTT-SBRT was successfully performed in all patients; the median treatment time was 28 min/fraction. The median follow-up period was 36.5 months. The 2-year LC, OS, and PFS rates were 98.0 %, 88.8 %, and 55.1 %, respectively. Disease progression was observed in 33 (68.8 %) patients. One patient (0.2 %) had local recurrence, 31 (64.6 %) developed new hepatic lesions outside the irradiation field, and nine (18.8 %) had distant metastases (including overlap). Grade 3 late adverse events were observed in seven patients (14.5 %). No grade 4 or 5 treatment-related toxicity was observed. The median tracking accuracy was 2.9 mm.
UNASSIGNED: Employing DTT-SBRT to treat liver tumors results in excellent LC with acceptable adverse-event incidence.
摘要：
UNASSIGNED：这项前瞻性多中心II期研究旨在评估动态肿瘤追踪（DTT）立体定向身体放射治疗（SBRT）的安全性和有效性，并使用万向节安装系统实时监测肝脏肿瘤。
UNASSIGNED：患有<4例原发性或转移性肝肿瘤且直径≤50mm且预期呼吸运动≥10mm的患者符合条件。处方剂量为五个部分的40Gy。主要终点是2年的局部控制（LC）。次要终点是总生存期（OS），无进展生存期（PFS），治疗相关毒性，跟踪精度。
UNASSIGNED：在2015年9月至2019年3月之间，来自四个机构的48例患者（48个病变）中位年龄为74岁。其中,39例诊断为肝细胞癌，9例诊断为转移性肝癌。中位肿瘤直径为17.5mm。所有患者均成功进行了DTT-SBRT；中位治疗时间为28分钟/分。中位随访期为36.5个月。2年LC,操作系统,PFS率为98.0%，88.8%,55.1%，分别。在33例（68.8%）患者中观察到疾病进展。1例（0.2%）局部复发，31(64.6%)在照射场外出现新的肝脏病变，9例（18.8%）有远处转移（包括重叠）。在7例患者中观察到3级晚期不良事件(14.5%)。未观察到4级或5级治疗相关毒性。中值跟踪精度为2.9mm。
UNASSIGNED：使用DTT-SBRT治疗肝脏肿瘤可产生优异的LC，不良事件发生率可接受。
UNASSIGNED：患有<4例原发性或转移性肝肿瘤且直径≤50mm且预期呼吸运动≥10mm的患者符合条件。
UNASSIGNED：在2015年9月至2019年3月之间，来自四个机构的48例患者（48个病变）中位年龄为74岁。
UNASSIGNED：使用DTT-SBRT治疗肝脏肿瘤可产生优异的LC，不良事件发生率可接受。
